By Rupa Shah, Head of Compliance at Releaf The conversation around workers’ rights and medical cannabis is still at a very early stage in the UK. Despite the fact that thousands of patients now access cannabis-based medicines legally through prescription, the framework remains poorly understood by [...]
Over the course of three years, across 13 regulated U.S. markets, BayMedica, a company specializing in the production and distribution of rare cannabinoids, identified three key insights into market demand for these compounds. First, products featuring THCV posted a 23.7% higher average retail margin than comparable [...]
Mental health advocate and one half of music duo Rizzle Kicks, Jordan Stephens, is collaborating with medical cannabis clinic, Alternaleaf, to shed light on the role of alternative treatments in supporting mental wellbeing. Stephens, who is currently touring with Rizzle Kicks as part of their comeback [...]
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years. While this has seen thousands of new patients gain access to medical cannabis, it still represents just a fraction [...]
A Yorkshire man, who supplied cannabis products to thousands of people with chronic illnesses, has been jailed for four years after his original suspended sentence was overturned. Joel Cunningham, 40, from Leeds, was convicted of seven offences, including possession with intent to supply magic mushrooms and [...]
Red Light Holland (CSE: TRIP) has established its foundation in the Netherlands, where psilocybin truffles, the underground sclerotia of psilocybin mushrooms, are legally permitted for cultivation and sale. The above-ground mushroom is prohibited, but the truffle is treated differently under Dutch law, despite delivering the same [...]
MJBizCon, the largest and one of the most influential gatherings in the cannabis industry, is adding a new element to its lineup: a cannabis competition. This year marks the debut of the MJBowl awards on December 4th in Las Vegas, produced in partnership with Budist, the [...]
In an industry defined by local operators struggling to stay afloat and confined within their borders, Michael Sassano, founder and CEO of Somai Pharmaceuticals, has created a blueprint for scaling cannabis worldwide with pharmaceutical discipline and regulatory agility. With headquarters in Lisbon and operations in [...]
Whether it’s a single retail license, a multi-site operation, or a vertically integrated enterprise, deals in Arizona are fetching top-tier premiums – often exceeding price points in larger, more mature markets like California. So, what’s driving these sky-high valuations? More importantly, how can industry players take [...]
Cannabis Health has partnered with leading experts at the Medical Cannabis Clinicians Society (MCCS) to bring its first educational event for healthcare professionals to the UK later this year. The Cannabis Health Symposium, taking place at Conway Hall in London on 25 November, 2025, will welcome [...]
New analysis has found that NHS access to medical cannabis could boost the UK’s economy by £13.3 billion over the next decade by returning thousands back to work. Widening NHS access to medical cannabis could add £4.5 billion to the economy over five years, and £13.3 [...]
Switching from smoking to dry-herb vaping offers a safer way to consume while also preserving the delicate terpene and cannabinoid profiles that contribute to the entourage effect. Unlike combustion, which produces tar, carbon monoxide, and other toxic byproducts, vaporization heats cannabis at controlled temperatures to release [...]
A major new study, analysing data from over four million adults in the US and Europe, has linked cannabis use to an almost quadrupling in the risk of developing type 2 diabetes. Cannabis use is increasing globally with an estimated 219 million users (4.3% of the [...]
The excitement and interest around New Jersey are impossible to ignore because of its potential to be one of the most lucrative cannabis markets in the country. Since legalization, operators have been racing to open doors, capture consumers, and keep pace with evolving regulations, as they [...]
The age of cannabis receiverships is here. If you’re a creditor, operator, landlord, or investor in a troubled cannabis business, you have a choice: watch value evaporate, or step up and run a disciplined, court-supervised sale that maximizes recoveries and preserves the company as a going [...]
Two new studies, one a large meta-analysis and the other real-world evidence from the UK, suggest that cannabis-based medicines, particularly those containing THC or mixed cannabinoids, may improve sleep quality and ease symptoms of insomnia. A new systematic review and meta-analysis, published in the journal Sleep [...]
The UK’s long-running project to regulate CBD (cannabidiol) products has taken another major step forward, seeing thousands of products make it to the final phase of the novel foods approval process. Yesterday, the Food Standards Agency (FSA) announced that its 12-week public consultation to discuss the [...]
Curaleaf Laboratories, part of Curaleaf International, today announced the UK launch of the Curaleaf Que Medical Inhalation Device (QMID), the first CE-certified liquid inhaler for cannabis-based medicines. Available on prescription, the device offers patients a precise, discreet, and clinically approved way to inhale cannabis-based treatments. Since [...]
Cannabis Health will host its first expert-led educational event for healthcare professionals later this year, with a focus on bridging the gap between policy and patient access. The one-day, CPD-accredited Cannabis Health Symposium, taking place at Conway Hall in London on Tuesday 25 November, 2025, is [...]
Despite a slow start in facilitating patient access to medical cannabis treatments, this is gradually changing for the better. The UK now has an active patient base of approximately 50,000-60,000, and an estimated 80,000 individuals are expected to receive treatment with CBPMs throughout 2025. The CQC [...]
Scientists in South Africa say they have found the first evidence of a rare class of phenolics, called ‘flavoalkaloids’, in leaves from the cannabis plant. Phenolic compounds, especially flavonoids, are well-known and sought after in the pharmaceutical industry because of their antioxidant, anti-inflammatory, and anti-carcinogenic properties. [...]
A new review has found ‘consistent evidence’ that cannabis improves sexual function in women, and should be considered as a first-line treatment for patients with female orgasm disorder (FOD). After reviewing findings from 16 peer-reviewed studies, including data from over 8,000 women, researchers have formally recommended [...]
A UK medical cannabis clinic is carrying out investigations after a substantial amount of patients’ information was leaked in a major data breach. In an email sent to patients on Monday 18 August, CB1 Medical confirmed it had identified a ‘data security incident’ when patients’ personal [...]
PatientsCann UK has raised urgent concerns with both the UK and Republic of Ireland (ROI) governments over the risks faced by patients prescribed medicines that are classified as Schedule 1 Controlled Drugs in one jurisdiction but legally prescribed in the other. At present, a prescription issued in the UK, ROI or Crown Dependencies cannot be dispensed across the border if the medicine is considered Schedule 1. More critically, patients cannot lawfully carry these prescribed medicines across the border, even if the crossing is unavoidable in order to travel within their own country. This issue disproportionately affects border communities, where travel across the border is not optional but a daily necessity. For patients in these communities, this creates an impossible situation: return home with their prescribed treatment and risk criminalisation, or forego essential medication. Couriers and healthcare professionals delivering medicines face the same challenge. Practical problems and risks The current situation gives rise to multiple, connected harms: Beyond individual harm, the problem creates wider public-health and administrative issues: increased emergency presentations, greater strain on social care and inequitable access to treatment depending on postcode. What PatientsCann UK is asking for PatientsCann UK has written to the governments of the UK and the Republic of Ireland requesting urgent clarification and guidance, including: The Northern Ireland Office has confirmed that officials are reviewing our letter. PatientsCann UK welcomes this development and will continue to press for clear, rapid action to protect patients who rely on any prescribed medicine. Sal Aziz, Director of PatientsCann UK, said: “Patients should never have to choose between taking their prescribed medicine and risking criminalisation. In practice this is what border communities on the island of Ireland face today. Governments must issue clear operational guidance and protections, urgently, so patients can continue to receive care without fear.” What happens next PatientsCann UK will publish updates as official responses are received. In the meantime, anyone affected by this issue is encouraged to contact PatientsCann UK so we can collate evidence and ensure our representations fully reflect the scale and immediacy of the problem. Please email info@patientscann.org.uk or send us a message on socials (Instagram | X).
The post Border Patients at Risk: PatientsCann Raises Concerns with UK & Ireland first appeared on PatientsCann UK.
A new survey of NHS doctors has highlighted a growing demand for alternative treatment options for complex health issues such as chronic pain and women’s health-related concerns. Out of 500 doctors currently practicing in the NHS, almost half of which were GPs, three quarters said that [...]
Ireland has become the latest jurisdiction to ban the use of the semi-synthetic cannabinoid HHC, with ministers raising concerns related to growing use among young people and risks to mental health. The decision, announced by the Department of Health on 29 July, sees Hexahydrocannabinol (HHC) classified as [...]
New research on a large data set of older adults suggests cannabis use may be linked to slower brain ageing and improved cognitive function. The study, which used data collected from 25,000 adults aged between 44 and 81 years, found that those who had consumed cannabis [...]
A new study is the first to confirm a link between an invasive fungal infection and a medical cannabis product sold to a patient in the US. A cancer patient, using medical cannabis to manage the side effects of chemotherapy, developed a life-threatening fungal infection after [...]
Just months ago, France’s long battle to establish a permanent generalised medical cannabis framework was on the brink of failure. Despite other major European countries looking to France’s 2019 pilot scheme for inspiration, COVID-19, waning political will, operational hurdles, and the dissolution of the National Assembly [...]
A recent study by researchers at the University of California San Diego School of Medicine has found that individuals with cannabis use disorder (CUD) are more than three times more likely to develop oral cancer within five years compared to those without CUD. In 2022, 17.7 [...]
The Care Quality Commission has raised a number of concerns related to the prescribing of cannabis-based products for medicinal use in the UK, as the latest data reveals further increases in private prescriptions. Earlier this month the independent regulator which is responsible for overseeing health and [...]
An international survey of people living with eating disorders has found that cannabis and psychedelics, such as ‘magic mushrooms’ or LSD, were best rated as alleviating symptoms by respondents who self-medicated with the non-prescribed drugs. The worst-rated drugs were alcohol, tobacco, nicotine and cocaine. Meanwhile, prescribed [...]
The European medical cannabis sector is experiencing unprecedented growth, driven by progressive legislation, expanding patient access, and a maturing supply chain, according to a new report. Findings from The European Cannabis Report: 10th Edition, published today (Tuesday 29 July), reflect a decade of immense change across European [...]
Current methods used by police to detect drug driving are not based on science, say the authors of a new paper calling for an overhaul of cannabis impairment testing. As cannabis becomes legal in a growing number of US states, public safety experts have raised concerns [...]
In a special edition of the Business of Cannabis Podcast, we go from ‘anecdote to evidence’ with Dr Anne Katrin Schlag, Head of Research and Interim CEO at Drug Science, and Graham Woodward, Chief Operating Officer at Releaf. Together, they explore how the UK can move [...]
Over four years after its slated launch, the NHS Cannabis Patient Registry is set to publish its first data. The years of obfuscation and delay prompted a Freedom of Information request by Business of Cannabis, which has established that the NHS will publish data from its ‘registry’ by the ‘end [...]
By Dr Sue Clenton, Medical Director, Rupa Shah, Chief Legal and Compliance Officer, and Graham Woodward, Chief Operations Officer, Releaf In a healthcare landscape as tightly regulated as the UK’s medical cannabis sector, building a clinical team isn’t just operational work, it’s mission-critical. With the field [...]
A new clinical trial will investigate the potential of cannabis-based treatment to improve quality of care for hospice eligible patients with dementia. The University of Maryland School of Medicine (UMSOM) Palliative Medicine Program has launched a new clinical trial funded by the National Institute on Aging [...]
It’s natural to have questions when considering a new medication, and for many exploring medical cannabis, a common query is about its effects, particularly the feeling often described as a “high.” While cannabis has a long history of medicinal use globally and became legal for medical [...]
Over the past eight months, Business of Cannabis, Cannabis Health, leafie and CannaReporter have conducted a wide-ranging investigation into Dr Green Digital Key — a high-profile blockchain project positioning itself as a game-changer in global cannabis access. Backed and vocally promoted by a man who styles [...]
Research from two separate studies has highlighted how promotional packaging and social media content can make cannabis-infused products more appealing to teens, prompting calls for more effective regulations. Bright colours, fruit imagery, and labels like “locally made” or “vegan” when used on packaging for cannabis edibles [...]
Patients have called for Switzerland’s new cannabis laws to address ‘unsatisfactory’ medical access ahead of an upcoming consultation on the draft legislation. As legislators look to make further reforms to Switzerland’s cannabis laws, campaigners are urging them to consider the daily realities of those who rely [...]
In the first controlled clinical trial of CBD in boys with autism, two-thirds of participants showed behavioural improvements with treatment, but there was also a significant placebo effect. Researchers at the Center for Medicinal Cannabis Research at University of California San Diego School of Medicine have [...]
The UK’s Food Standards Agency (FSA) has announced some significant updates to its multi-year CBD Novel Foods approvals process, finally offering hundreds of long-suffering businesses some light at the end of the tunnel. Following suggestions from the FSA late last year that it planned to ‘clearly communicate [...]
A brutally honest call-in to the UK medical cannabis patient community, about ego, division, and why we’re our own worst enemy.
The post This Isn’t a Movement, It’s a Mess first appeared on PatientsCann UK.
Words by Dr Sue Clenton, Medical Director, Releaf Over the past year, we’ve seen medical cannabis move from the margins toward the mainstream — not through media headlines or marketing campaigns, but in clinics, in consultations, and in the steady accumulation of patient outcomes. At Releaf, [...]
Patients in Australia living with endometriosis say cannabis is more-effective for managing their symptoms, and has fewer side-effects than pharmaceutical medications, a new survey finds. According to new survey data published in the journal Reproduction & Fertility, the majority of patients using cannabis to manage symptoms of endometriosis, find [...]
Ukraine has officially issued its first ever permit for medical cannabis to be imported into the country, bringing patients one step closer to receiving treatment. It represents the latest development in Ukraine’s nascent but rapidly evolving medical cannabis programme, after the country officially enshrined it into law [...]
Ahead of European Cannabis Week, Grow Group’s Managing Director, Pierre van Weperen, talks to Cannabis Health about the current state of play, and the future of cannabis-based medicine in the UK. More than 6.4 million people in the UK are currently waiting for treatment on the [...]
A national class action has been brought against Aurora Cannabis in Canada, alleging that the company ‘negligently’ failed to warn consumers about the risk of developing Cannabinoid Hyperemesis Syndrome (CHS). On May 14, 2025, the Ontario Superior Court of Justice certified a national class action alleging [...]
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
